Enfortumab vedotin
- Generic Name
- Enfortumab vedotin
- Brand Names
- 备思复
PADCEV-KEYTRUDA Combination Shows Sustained Survival Benefit in Advanced Urothelial Cancer Trial
• Phase 3 EV-302 trial demonstrates PADCEV plus KEYTRUDA reduces mortality risk by 49% compared to chemotherapy in advanced urothelial cancer patients, with median overall survival of 33.8 months versus 15.9 months.
• The combination therapy showed significant progression-free survival benefit of 12.5 months compared to 6.3 months with chemotherapy, representing a 52% reduction in disease progression risk.
• Extended 12-month follow-up data confirms sustained efficacy across all patient subgroups, including both cisplatin eligible and ineligible patients, with no new safety concerns identified.
Novel Therapies and Biomarkers Reshape Bladder Cancer Treatment Strategies
• Immunotherapy and antibody-drug conjugates (ADCs) are transforming urothelial carcinoma treatment, prompting investigation into bladder-sparing approaches.
• Ongoing trials are evaluating combinations of ICIs or ADCs with trimodal therapy (TMT) in muscle-invasive bladder cancer (MIBC) patients.
• Predictive biomarkers like ERCC2 mutations and ctDNA levels show promise in tailoring treatment and predicting outcomes in MIBC.
• Combining ADCs with radiation therapy demonstrates potential in preclinical studies, warranting further clinical investigation for enhanced efficacy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath